Certara Announces New Release of Integral® Software
Latest version enhances efficiency, compliance, and user experience for PK scientists Radnor, PA. — December…
Danielle PillsburyDecember 16, 2025
Using M&S to Evaluate Oncology Drug Dosing
Learn how modeling & simulation improves oncology drug dosing, optimizing safety, efficacy, and personalized treatment…
CertaraNovember 14, 2025
ACoP 2025 Insights: Scaling the Future of QSP Modeling with Certara IQ™
At ACoP 2025, Certara showcased innovation with the launch of Certara IQ™ and Phoenix® Cloud,…
CertaraNovember 13, 2025
Seeing Across Species: Empiric Pharmacokinetic Time-Course Scaling in Phoenix®
Watch our on-demand webinar on empiric PK time-course scaling and learn how Certara’s translational experts…
CertaraNovember 13, 2025
Exposure–Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema
Certara and Ionis analyzed Phase 3 OASIS-HAE data showing flexible, effective donidalorsen dosing can reduce…
CertaraNovember 12, 2025
Supporting KalVista’s NDA Submission for a Novel HAE Treatment
To accelerate the first oral therapy for hereditary angioedema (HAE), KalVista Pharmaceuticals partnered with Certara…
Danielle PillsburyNovember 12, 2025
Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling
Discover how Certara applied exposure-response analysis and advanced modeling to optimize Donidalorsen dosing for hereditary…
CertaraNovember 10, 2025
Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns
Improve pediatric drug development with Certara’s Pediatric Practice, MIDD expertise for PIPs/PSPs, dose selection, regulatory…
CertaraNovember 10, 2025
